Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

After years of delays and debate, 2024 was the year when several health initiatives started to move forward. And advocates ...

Medicare, in collaboration with Medicaid, has negotiated with pharmaceutical companies to reduce the prices of ten high-cost, ...

Of patients who met the high-risk criteria, 55% were not on American Diabetes Association (ADA) guideline-directed medication therapy ... include empagliflozin (Jardiance) and dapagliflozin ...

Hospitalisations account for up to 70% of total healthcare costs for people with ... The new approval comes shortly after Jardiance became the first SGLT2 drug to be approved by the FDA in ...

Most notable is Eli Lilly/Boehringer’s Jardiance, which has broken new ground by being the first diabetes drug licensed to claim ... metformin combination will cost $3,263 a year, while ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

GLP-1 drugs, including Ozempic, Monjauro and Rybelsus, treat type 2 diabetes. The drugs can cost more than $1,000 a month SGLT-2 drugs include Jardiance, Farxiga and Invokana. Here are five numbers to ...